Takeda Pharmaceutical Company Limited (“Takeda”) today announced that it has received approval from the Japan Ministry of Health, Labour and Welfare to manufacture and market Alofisel (darvadstrocel) - development code: Cx601 - for the treatment of complex perianal fistulas in patients with non-active or mildly active luminal Crohn’s disease (CD).This product is indicated for the treatment of patients who have shown an inadequate response to at least one existing medicinal treatment.
CD is a chronic inflammatory disease of the digestive system,4 which affects an estimated 70,700 people in Japan. People living with CD may experience complex perianal fistulas, which can cause intense pain, bleeding, swelling, infection, and anal discharge. Despite medical and surgical advancements, complex perianal fistulas in CD remain challenging for clinicians to treat.7 In a survey commissioned and conducted by the European Federation of Crohn's & Ulcerative Colitis Associations ("EFCCA"), in collaboration with Takeda, CD patients living with perianal fistulas reported a negative impact on many aspects of their quality of life, including the ability to do sports, work and employment, dating and sexual life. Patients also reported feeling more unhygienic, uncomfortable, and guilty about their condition compared to CD patients without perianal fistulas.
“We are delighted that Alofisel has been approved in Japan for the treatment of complex perianal fistulas in Crohn’s disease patients. Complex perianal fistulas are a challenging complication of Crohn’s disease, and the approval of the first expanded human allogeneic adipose-derived mesenchymal stem cell therapy in Japan offers a potential cell-mediated closure option to patients who do not respond to conventional or biologic therapies,” said Naoyoshi Hirota, General Manager of Takeda Development Center Japan.
by Route of Administration (Oral, Injectors, Implantable, Syrups, Gels, Pulmonary, Solutions, Tablets, Syringes), Application (Cancer, Diabetes), Facility of Use (Hospitals), COVID-19 ImpactDownload free sample pages
The approval is based on data from two trials, the Japanese Study Darvadstrocel-3002 and the ADMIRE-CD trial, conducted in Europe and Israel:
Alofisel is the first expanded human allogeneic adipose-derived mesenchymal stem cell therapy to be approved in Japan. By exhibiting immunomodulatory and local anti-inflammatory effects at the site of inflammation, it offers a new treatment option with the potential of cell-mediated closure for complex perianal fistulas in patients with non-active or mildly active luminal Crohn’s disease who have shown an inadequate response to at least one existing medicinal treatment.
It is a made to order therapy that must be administered within 72 hours of manufacture. Takeda has established a manufacturing and logistics system in Japan that enables delivery to medical institutions nationwide under strict temperature control.
Alofisel is a suspension of allogeneic (or donor-derived) expanded adipose-derived stem cells (eASC) for the treatment of complex perianal fistulas in adult patients with non-active or mildly active luminal CD. Alofisel was granted orphan drug designation by the European Commission in 2009. the U.S. Food and Drug Administration (FDA) in 2017, and the Japanese Ministry of Health, Labour and Welfare on March, 2019 Alofisel received central marketing authorization approval in the European Union in March 2018 for the treatment of complex perianal fistulas in adult patients with non-active/mildly active luminal Crohn's disease, when fistulas have shown an inadequate response to at least one conventional or biologic therapy. In 2019, darvadstrocel received a Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. FDA for complex perianal fistulas in adults with CD.
Alofisel is approved in the European Union/European Economic Area, Israel, Switzerland and the United Kingdom for the treatment of complex perianal fistulas in adult patients with non-active/mildly active luminal Crohn’s disease, when fistulas have shown an inadequate response to at least one conventional or biologic therapy Alofisel should be used only after conditioning of the fistulas.
In Japan, Alofisel is indicated for the treatment of complex perianal fistulas in patients with non-active or mildly active luminal Crohn’s disease (CD). This product is indicated for the treatment of patients who have shown an inadequate response to at least one existing medicinal treatment.
Important Safety Information
Hypersensitivity to the active substance, bovine serum or to any of the excipients.
Special warnings and special precautions for use
Darvadstrocel may contain trace amounts of either gentamicin or benzylpenicillin and streptomycin. This should be considered in patients with known hypersensitivity to these classes of antibiotics. Local anesthesia is not recommended due to the unknown effect of local anesthetics on the injected cells.
The injection of any substance other than sodium chloride 9 mg/mL (0.9%) (e.g. hydrogen peroxide, methylene blue, iodine solutions or hypertonic glucose solutions) through the fistula tracts is not allowed before, during, or after the injection of darvadstrocel as this may compromise cell viability.
Darvadstrocel is indicated for injection in the fistula tract tissue only. Darvadstrocel must not be administered using a needle thinner than 22G. Thinner gauge needles can cause cell disruption during injection and may compromise cell viability.
As darvadstrocel is a living stem cell therapy, it cannot be sterilized, and therefore could contain potentially infected biological material, although the risk is considered to be low and controlled in the manufacturing process. Patients should be followed up for potential signs of infection after administration.
Darvadstrocel should only be administered by specialist physicians experienced in the diagnosis and treatment of conditions for which Darvadstrocel is indicated.
Fertility, Pregnancy & Lactation
No data is available from the use of darvadstrocel in pregnant or breast-feeding women. Darvadstrocel is not recommended during pregnancy and in women of childbearing potential who are not using contraception. As a precautionary measure, darvadstrocel is not recommended for administration during breast-feeding.
Adverse reactions include: Common (≥1/100 to <1/10): anal abscess, proctalgia, anal fistula and procedural pain. Conditioning of fistulas has been associated with proctalgia and procedural pain
Date: Sep 27, 2021
Share this news: